Tag: Ticagrelor

1. Patients status-post placement of drug-eluting stents (DES) for acute coronary syndrome received three months of Ticagrelor and Aspirin dual-antiplatelet therapy (DAPT), followed by nine months of DAPT or Ticagrelor monotherapy. 2. At one year, patients who received Ticagrelor alone experienced significantly fewer adverse major bleeding events. There was no...
1. In this modern population of Canadian patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), the rates of major adverse cardiovascular events (MACE) at 1 year follow-up were the same in groups treated with ticagrelor or clopidogrel. Ticagrelor was linked with a higher risk of...
1. Bleeding after percutaneous coronary intervention (PCI) was more common in women, but the effect of two antiplatelet strategies on death and new Q-wave myocardial infarction following PCI did not differ between men and women. Evidence Rating Level: 1 (Excellent) Percutaneous coronary intervention (PCI) is a highly effective treatment in coronary...
Bleeding after percutaneous coronary intervention (PCI) was more common in women, but the effect of two antiplatelet strategies on death and new Q-wave myocardial infarction following PCI did not differ between men and women. Evidence Rating Level: 1 (Excellent) Percutaneous coronary intervention (PCI) is a highly effective treatment in coronary...
1. In this pre-specified ancillary study of a randomized control trial, ticagrelor alone after one month was found non-inferior, but not superior, to dual antiplatelet therapy in preventing ischemic events after drug eluting coronary stenting. 2. Ticagrelor did not decrease bleeding risk compared with dual antiplatelet therapy. Evidence Rating Level: 2...
1. A monoclonal antibody fragment to ticagrelor, PB2452, increased platelet function significantly in healthy patients given the oral P2Y12 inhibitor ticagrelor. 2. Adverse effects were mainly limited to the infusion site, with limited systemic events. Evidence Rating Level: 1 (Excellent)       Study Rundown: Antiplatelet therapy is used extensively for prevention of cardiovascular occlusive events. Many...
1. A monoclonal antibody fragment to ticagrelor, PB2452, increased platelet function significantly in healthy patients given the oral P2Y12 inhibitor ticagrelor. 2. Adverse effects were mainly limited to the infusion site, with limited systemic events. Evidence Rating Level: 1 (Excellent)       Study Rundown: Antiplatelet therapy is used extensively for prevention of cardiovascular occlusive...
1. In this randomized controlled trial, medication vouchers were associated with a small increase in patient-reported persistence with P2Y12 inhibitors for patients who had suffered a myocardial infarction (MI). 2. Medication vouchers were not associated with reduced major adverse cardiovascular events (MACE) in these patients. Evidence Rating Level: 1 (Excellent)       Study Rundown: Antiplatelet therapy,...
1. In this randomized controlled trial, medication vouchers were associated with a small increase in patient-reported persistence with P2Y12 inhibitors for patients who had suffered a myocardial infarction (MI). 2. Medication vouchers were not associated with reduced major adverse cardiovascular events (MACE) in these patients. Evidence Rating Level: 1 (Excellent)       Study Rundown:...
1. Use of ticagrelor resulted in similar rates of major bleeding compared to clopidogrel in patients with ST elevation myocardial infarction treated with thrombolysis. Evidence Rating Level: 2 (Good) Study Rundown: Antiplatelet therapy is a major component of management of acute myocardial infarction. Ticagrelor results in greater and more rapid P2Y12...